Emcure Pharmaceuticals has officially announced a strategic distribution agreement with global pharmaceutical giant Roche for nephrology and transplant products in the Indian market. The partnership, formalized through a press release dated March 2, 2026, will commence on April 1, 2026, marking a significant expansion in Emcure's therapeutic portfolio.

Partnership Details

The distribution agreement encompasses three specialized pharmaceutical brands essential in nephrology and transplant care:

Leadership Perspectives

Satish Mehta, Managing Director & CEO of Emcure Pharmaceuticals, commented on the partnership: "This partnership with Roche is a natural extension of Emcure's commitment to improving outcomes in anemia and renal care. Roche's globally trusted innovations strongly complement our existing portfolio and reach."

Rajji Mehdwan, Managing Director & CEO of Roche India & Neighbouring Markets, stated: "We are pleased to partner with Emcure Pharmaceuticals, a company with deep expertise and leadership in anemia management and nephrology. Through Emcure's strong distribution network and clinical engagement, we believe these medicines can reach a larger number of patients."

Strategic Market Position

Emcure Pharmaceuticals is recognized as a market leader in anemia management and maintains a strong presence across nephrology and chronic kidney disease segments. The company is ranked as the 13th largest pharmaceutical company in India in terms of domestic sales for MAT October 2025, with operations spanning over 70 countries globally.

Product Portfolio Enhancement

The collaboration focuses on expanding patient access to critical therapies in chronic kidney disease, anemia management, and transplant care across India. CellCept® represents Roche's original innovation supporting organ transplants worldwide, while Mircera® offers long-acting treatment with dosing flexibility of once every 2-4 weeks for chronic kidney disease patients.

Implementation and Market Impact

The partnership leverages Emcure's established distribution network and clinical engagement capabilities to improve patient access to proven therapies. The collaboration aims to support physicians in delivering optimal care while enhancing anemia management and long-term outcomes for patients with chronic kidney disease and transplant requirements.

Emcure Pharmaceuticals Limited has informed stock exchanges about a fire incident at its manufacturing facility in Hinjawadi, Pune, Maharashtra on February 07, 2026. The incident occurred at the utility block of Plant I, temporarily disrupting operations at the facility.

Incident Details and Impact

The fire incident took place on February 07, 2026, affecting the utility block of the company's manufacturing plant located at Hinjawadi, Pune. While the fire has been successfully controlled, the cause remains under investigation. The company confirmed that no human injuries or casualties were reported during the incident.

Operational Disruption and Recovery

The fire incident has resulted in temporary disruption of operations at the affected manufacturing plant. The company estimates that operations will remain suspended for a period of 5 to 7 days. Emcure Pharmaceuticals is implementing all necessary measures to restore plant operations at the earliest possible time.

Insurance Coverage and Financial Impact

The company has confirmed that adequate insurance coverage exists for the affected plant. Emcure Pharmaceuticals has already notified the insurance company about the incident and initiated the claims process. According to the company's assessment, the incident is not expected to have a material impact on the company's financial performance, though the full extent of loss and damage is currently being evaluated.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has committed to providing further updates on any developments related to this incident within due time. The communication was signed by Tajuddin Shaikh, Chief Financial Officer of Emcure Pharmaceuticals Limited.